SCHEMBL13199109

SCHEMBL13199109

O=C(Cc1cccc(O)c1)NNC(=O)c1ccc(OCc2ccccc2)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PLAU P00749 1/20 0.61
▸ ELANE P08246 1/20 0.61
▸ HDAC3 O15379 1/20 0.55
▸ HDAC1 Q13547 1/20 0.55
▸ HDAC2 Q92769 1/20 0.55
▸ NCOR2 Q9Y618 1/20 0.55
▸ NR1H4 Q96RI1 1/20 0.55
▸ NR4A1 P22736 1/20 0.54
▸ NR4A2 P43354 1/20 0.54
▸ NR4A3 Q92570 1/20 0.54
▸ NPC1 O15118 2/20 0.53
▸ RAB9A P51151 2/20 0.53
▸ SMN1; SMN2 Q16637 2/20 0.53
▸ ALDH1A1 P00352 2/20 0.52
▸ PTPRC P08575 1/20 0.52
▸ PTPN1 P18031 1/20 0.52
▸ MAPT P10636 1/20 0.52
▸ KDM4E B2RXH2 2/20 0.52
▸ MEN1 O00255 2/20 0.52
▸ KMT2A Q03164 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13199121 0.89 SMPD1 (0.64) NR1H4NR4A2PTPN1MEN1KMT2A
SCHEMBL13199231 0.87 TDP1 (0.62) PLAUELANESMN1; SMN2ALDH1A1KDM4E
SCHEMBL13199209 0.85 PLAU (0.76) PLAUELANENPC1RAB9ASMN1; SMN2
SCHEMBL13199110 0.84 KDM4E (0.55) PLAUELANEALDH1A1KDM4EMEN1
SCHEMBL2951993 0.83 SMPD1 (0.44) PLAUELANENR4A2NPC1MEN1
SCHEMBL13199130 0.82 MEN1 (0.60) PLAUELANEHDAC1NR4A2NPC1
SCHEMBL2951792 0.82 MAOB (0.50) PLAUELANENR4A2NPC1RAB9A
SCHEMBL13199142 0.81 NLRP3 (0.60) PLAUELANEHDAC3HDAC1HDAC2
SCHEMBL13199138 0.81 NPC1 (0.51) PLAUELANENPC1RAB9ASMN1; SMN2
SCHEMBL13199199 0.81 NLRP3 (0.56) PLAUELANEHDAC3HDAC1HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7767716-B2 Acyl hydrazines as kinase inhibitors, in particular for SGK MERCK PATENT GMBH (DE) 2010-08-03 — — US disclosed
US-7767716-B2 Acyl hydrazines as kinase inhibitors, in particular for SGK MERCK PATENT GMBH (DE) 2010-08-03 — — US disclosed
EP-1866280-B1 ACYL HYDRAZIDES AS KINASE INHIBITORS, IN PARTICULAR FOR SGK MERCK PATENT GMBH (DE) 2008-08-13 — — EP disclosed
US-20080167380-A1 Acyl Hydrazines as Kinase Inhibitors, in Particular for Sgk MERCK PATENT GMBH (DE) 2008-07-10 — — US disclosed
US-20080167380-A1 Acyl Hydrazines as Kinase Inhibitors, in Particular for Sgk MERCK PATENT GMBH (DE) 2008-07-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080167380-A1 Acyl Hydrazines as Kinase Inhibitors, in Particular for Sgk SGK1, AGK, SGK2 PLAU 2508/4885ELANE 3387/4885HDAC3 73/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback